Drug Interactions to Know About

Most peptide users are on something else too. Blood pressure medication, an SSRI, metformin, thyroid replacement, a statin. Adding a peptide on top isn't inherently a problem — but some combinations interact in ways that matter.

This isn't a pharmacology textbook. It's the set of interactions that come up often enough in real-world use that if you're on the medication, you should know about them before you reach for the peptide.

The general principle

Peptides interact with other drugs through a few recurring mechanisms:

1. Overlapping effect on the same system — a GLP-1 plus insulin both lower blood glucose. Stack them without dose adjustment and you get hypoglycemia.
2. Altered absorption — GLP-1s slow gastric emptying, which delays absorption of oral medications.
3. Shared receptor targets — serotonergic peptides plus serotonergic drugs can additively tip toward serotonin excess.
4. Shared metabolic fate — peptides don't usually go through CYP450 enzymes the way small molecules do, so traditional pharmacokinetic interactions are less common here than with oral drugs.

The most dangerous interactions tend to be category 1 and 3.

GLP-1 interactions (semaglutide, tirzepatide, retatrutide)

Medication class	What happens	How to handle
Insulin	Additive hypoglycemia, especially during titration	Insulin dose typically needs reduction — clinician decision
Sulfonylureas (glipizide, glyburide)	Hypoglycemia risk	Sulfonylurea dose usually reduced at GLP-1 start
Metformin	No dangerous interaction; often used together. GI side effects compound.	Start one at a time; titrate slowly
SGLT2 inhibitors (empagliflozin, dapagliflozin)	Additive dehydration risk if GI side effects bad	Hydrate aggressively
Oral contraceptives	Slowed gastric emptying may reduce efficacy of oral OCPs in first weeks	Backup contraception during titration
Levothyroxine	Absorption may be delayed or altered	Take at consistent time; recheck TSH 6–8 weeks in
Warfarin	Absorption changes can shift INR	Monitor INR more frequently during titration
Oral antibiotics, oral bisphosphonates	Delayed absorption	Take on consistent schedule; follow drug-specific instructions

The recurring theme: slowed gastric emptying makes oral drug timing matter more than usual. Nothing catastrophic, but if you're on an oral medication where absorption timing matters, talk to your prescriber.

GH axis peptide interactions (sermorelin, ipamorelin, CJC-1295, tesamorelin, MK-677)

Medication class	What happens	How to handle
Insulin / diabetes medications	GH antagonizes insulin — glucose rises, insulin may need adjustment upward	Monitor glucose closely; clinician decision
Corticosteroids (prednisone, hydrocortisone)	Blunt GH response; also both raise glucose	Expect muted peptide effects
Thyroid hormone	GH converts T4 to T3 more aggressively; sometimes you need less T4	Recheck TSH / free T4 at 8 weeks
Opioids	Can blunt GH release at baseline	Expect reduced peptide effect
Levodopa	Stimulates GH release — additive with GH secretagogues	Usually manageable, just be aware

The big one is the glucose interaction. If you're diabetic and you start a GH peptide without monitoring glucose, you will miss the drift until it's pronounced.

PT-141 / bremelanotide (sexual function)

Medication class	What happens	How to handle
Antihypertensives (any)	PT-141 raises BP transiently; can counteract medication	Monitor BP; don't stack on the day of a major dose
Alpha blockers (tamsulosin, doxazosin)	Manufacturer specifically warns against — significant BP effects	Avoid combination
PDE5 inhibitors (sildenafil, tadalafil)	Opposite BP effects; manufacturer advises separation of 24 hours	Separate dosing
Stimulants / sympathomimetics	Additive BP and heart rate elevation	Caution
SSRIs, SNRIs	PT-141 can interact with serotonergic tone; mood effects reported	Lower dose, monitor mood

PT-141 is the peptide with the most medication-interaction awareness needed, because it acts on a system (melanocortin → sympathetic nervous system) that overlaps with a lot of common prescriptions.

Cognitive and serotonergic peptides

Peptide	Medication class	What happens
Semax, Selank	MAOIs, SSRIs, SNRIs, tramadol, triptans	Theoretical serotonin syndrome risk; data is thin, community reports mostly uneventful — but caution is reasonable
Selank	Benzodiazepines	Additive anxiolysis; generally benign but start low
Cerebrolysin	MAOIs	Contraindicated per manufacturer

Healing peptides (BPC-157, TB-500, GHK-Cu)

The good news: these have minimal documented drug interactions. The community experience over years of use hasn't surfaced much.

Worth knowing anyway:

• NSAIDs — there's speculation that chronic NSAID use blunts BPC-157's gastric-protective effect, but the peptide still seems to work with them. Not a contraindication, just something to be aware of.
• Anticoagulants (warfarin, rivaroxaban, apixaban) — BPC-157 has some effects on vascular tone and clotting; no documented catastrophic interactions, but worth monitoring bruising and any lab signals if you're on chronic anticoagulation.

Melanotan II

Medication class	What happens
Antihypertensives	Melanotan II can raise BP; may reduce medication effectiveness
Beta blockers	Complex interaction on autonomic tone; caution
Any immunosuppressant	Pigmentation changes may obscure skin cancer detection — more a monitoring problem than a pharmacological one

Thymic peptides (thymosin alpha-1)

Medication class	What happens
Immunosuppressants (post-transplant, for autoimmune disease)	Directly opposite mechanism — avoid
Systemic chemotherapy	Has been used adjunctively in some oncology contexts, but only under clinical direction

The medications people forget to mention

Three categories show up in post-incident forum threads more often than you'd expect:

1. Supplements that act like drugs — berberine (glucose lowering, additive with GLP-1s), bitter melon (same), high-dose melatonin (additive with DSIP / epithalon), ashwagandha (thyroid effects that compound with GH peptides).
2. Recent antibiotics — altered gut motility and microbiome shifts can amplify GLP-1 GI side effects for weeks after a course.
3. Recreational substances — stimulants plus PT-141 or melanotan II, opioids blunting GH peptide effect, MDMA plus any serotonergic peptide. Community wisdom: don't stack those experiences with new peptide introductions.

When to stop and see a doctor

Any new symptom on a drug-plus-peptide combination that you can't clearly attribute to one or the other warrants pausing the peptide first. The prescription medication has established safety data and is doing something you've already committed to. The peptide is the variable — pull it, see if the symptom resolves. If you have a prescriber, tell them what you're taking. "I'm on X, Y, and Z" is useful information for them whether or not they approve. A prescriber who knows gets to adjust doses, check the right labs, and catch problems early.

Where to go next

• Contraindications by peptide class covers the underlying conditions (not medications) that rule out specific peptides.
• Red flags: when to stop a protocol immediately is the symptom list for mid-cycle.
• For specific interaction questions, the Bloodwork & Metrics forum often has people with direct experience of the combination you're considering.

---

This is educational content, not medical advice. Abnormal labs or symptoms warrant consultation with a qualified healthcare provider.